Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company"). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Halozyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On November 26, 2018, Halozyme issued a press release announcing "that prior to data analysis, the [U.S. Food and Drug Administration] has agreed to Halozyme's request to change the primary endpoint of the HALO-301 study to the single primary endpoint of overall survival (OS). As a result, the previously planned interim analysis will not be conducted."
Following this announcement, Halozyme's stock price fell $1.24 per share, or 7.42%, to close at $15.47 per share on November 27, 2018.